<DOC>
	<DOC>NCT01915784</DOC>
	<brief_summary>Preference study: Genuair® (Pressair™) vs Breezhaler® (Neohaler™) inhalers in patients with COPD</brief_summary>
	<brief_title>Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Adult male or female patients aged ≥40 years with stable moderatetosevere COPD according to the GOLD Guidelines classification (grades II and III): forced expiratory volume in 1 second (measured between 10 to 15 minutes postinhalation of 400 μg of salbutamol) is 30%≤FEV1&lt;80% of the predicted normal value Patients naïve to both study inhaler devices, Genuair® and Breezhaler®, for at least 2 years Agreement to participate and voluntarily sign the informed consent form Patients with other clinically significant uncontrolled chronic diseases, particularly body malformations or diseases affecting coordination and/or motor system Patients unable to read product package instructions and answer patient reported questionnaires (PASAPQ) Patients with any other serious or uncontrolled mental health problems Patients currently participating in other randomised clinical studies Patients with COPD exacerbation within 6 weeks before Visit 1 and patient hospitalised for COPD exacerbation within 3 months prior to Visit 1 Patients with any other conditions that, in the investigator's opinion, might indicate the patient to be inappropriate for the study Patient likely to be uncooperative</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>